Assenagon Asset Management S.A. Aldeyra Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$5.08 - $7.09 $2,286 - $3,190	-450 Reduced 0.07%	645,020 $4.49 Million
Q3 2022 Oct 27, 2022	SELL	$3.8 - $7.74 $5,118 - $10,425	-1,347 Reduced 0.21%	645,470 $3.45 Million
Q2 2022 Jul 27, 2022	SELL	$2.43 - $4.85 $797,822 - $1.59 Million	-328,322 Reduced 33.67%	646,817 $2.58 Million
Q1 2022 Apr 25, 2022	BUY	$3.25 - $5.17 $3.08 Million - $4.91 Million	948,747 Added 3594.83%	975,139 $4.33 Million
Q4 2021 Feb 01, 2022	SELL	$3.5 - $9.63 $149,894 - $412,424	-42,827 Reduced 61.87%	26,392 $106,000
Q3 2021 Oct 19, 2021	SELL	$7.94 - $11.31 $4.52 Million - $6.44 Million	-569,094 Reduced 89.16%	69,219 $608,000
Q2 2021 Jul 15, 2021	BUY	$10.44 - $14.85 $6.1 Million - $8.68 Million	584,539 Added 1087.03%	638,313 $7.23 Million
Q1 2021 Apr 26, 2021	SELL	$6.53 - $14.42 $1.41 Million - $3.11 Million	-215,409 Reduced 80.02%	53,774 $639,000
Q4 2020 Feb 01, 2021	SELL	$6.31 - $8.13 $1.29 Million - $1.67 Million	-205,093 Reduced 43.24%	269,183 $1.85 Million
Q3 2020 Oct 07, 2020	BUY	$4.0 - $7.53 $1.9 Million - $3.57 Million	474,276 New	474,276 $3.51 Million

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.